Opal Therapeutics Lands $1.25M NSF Award for Uterine Organoids

Opal Therapeutics has secured a $1.25M NSF SBIR Phase II award to scale its patient-derived uterine organoid platform for women’s health drug discovery. Founded in 2023 in San Francisco by Dr. Morgan Stanton, PhD, the biotechnology company develops endometrial and myometrial organoids for research into endometriosis, fibroids, and other gynecological conditions.

The money matters, but the model matters more. Rodents cannot reproduce human menstrual-cycle biology, creating an awkward scientific reality when the objective is developing therapies for distinctly human reproductive conditions. Opal Therapeutics is building human-derived models designed to give drug developers another way to interrogate that biology.

The National Science Foundation is the sole confirmed funder of the Phase II award. Opal will use the non-dilutive capital to expand lab infrastructure, organoid manufacturing capacity, and imaging and inflammation assay throughput. The company previously received approximately $275K in NSF funding. For drug developers, the larger question is straightforward: what changes when women’s health research gets models built around the human biology researchers were trying to understand in the first place?

What Happened

Opal Therapeutics secured a $1.25M NSF SBIR Phase II award to expand its uterine organoid technology and drug-discovery infrastructure. The funding was announced in August 2026 and represents another step in the San Francisco biotechnology company’s development. Dr. Morgan Stanton founded Opal Therapeutics in 2023 and serves as CEO. Dr. Morgan Stanton holds a PhD in Chemistry from Worcester Polytechnic Institute, completed postdoctoral research at the Max Planck Institute for Intelligent Systems, and previously served in discovery biology leadership at Herophilus.

Opal develops patient-derived uterine organoids, including endometrial and myometrial models, for drug discovery involving endometriosis, fibroids, and other gynecological conditions. The $1.25M award will fund expanded laboratory infrastructure, increased organoid manufacturing capacity, and greater imaging and inflammation assay throughput. Unlike a traditional venture round, the NSF award provides non-dilutive federal capital. The company did not disclose a valuation, and no venture investors are confirmed.

Why This Matters

Women’s health drug discovery has a model problem hiding inside the larger therapeutic problem. Rodent models cannot replicate human menstrual-cycle biology. That limitation becomes difficult to ignore when researchers are studying diseases involving reproductive tissues and biological processes that are distinctly human. Opal Therapeutics is approaching the problem by creating patient-derived uterine models that can be produced at scale.

Patient-derived organoids do not guarantee successful drugs, and pretending otherwise would turn science into marketing with better lab coats. Their strategic value is more precise: more relevant biological models can give researchers another environment for evaluating compounds, investigating disease biology, and challenging assumptions before programs move further through development. For pharmaceutical and biotechnology companies working in women’s health, better discovery infrastructure can affect which questions become practical to investigate and how quickly weak hypotheses encounter human biology. That makes Opal an infrastructure story as much as a therapeutics story.

From Scientific Platform to Commercial Signal

Opal Therapeutics has reported producing organoids at a scale of tens of thousands. The company also secured menstrual-health company Papaya as its 1st paid customer and signed a Material Transfer Agreement with Baylor College of Medicine to expand its tissue biobank. Those milestones give the $1.25M NSF award context.

Opal has been building technical infrastructure, establishing commercial demand, expanding access to biological material, and now securing capital specifically directed toward additional scale. It is a more instructive sequence than raising money first and spending the next 18 months explaining what everybody is supposedly waiting to buy. For early-stage biotechnology companies, non-dilutive financing can create strategic breathing room. Opal previously received approximately $275K in NSF funding, while its latest $1.25M Phase II award allows the company to expand technical capability without making equity dilution the immediate price of that expansion. The lesson is narrower and more useful than grants versus venture capital: match the capital source to the technical milestone.

The Team Behind Opal Therapeutics

Dr. Morgan Stanton, CEO, combines scientific training with drug-discovery experience. Opal also has an advisory group spanning reproductive biology, biotechnology, therapeutic discovery, operations, and commercialization. Current advisors include Dr. Aabid Shariff, PhD; Dr. Matteo A. Molè, PhD; Carolyn Kreuzkamp, MBA; Alexia Krispin, MBA; Dr. Scott Lundeen, PhD; Dr. Jean-Charles JC Neel, PhD; and Dr. Hugh Taylor.

For an early-stage scientific company, that combination matters because the challenge is not simply proving that an organoid can be made. The company has to turn biological capability into repeatable infrastructure that researchers and commercial customers can actually use. The laboratory achievement and the business model eventually have to meet each other.

What Opal Therapeutics Signals for Women’s Health

The strategic importance of Opal Therapeutics sits beyond a single $1.25M award. Drug discovery depends heavily on the quality and relevance of the systems used to investigate disease and evaluate potential treatments. In women’s health, Opal is targeting a specific limitation: conventional animal models cannot fully reproduce the reproductive biology researchers need to study.

Scaling patient-derived uterine organoids could give pharmaceutical and biotechnology teams another tool for deciding which compounds deserve additional resources and which assumptions need to die young and cheaply. That last part is underrated. Drug discovery is not only a search for promising answers. It is an expensive process of discovering which answers are wrong.

Opal is therefore building at an interesting intersection of women’s health, biotechnology infrastructure, organoid technology, and drug discovery. The NSF award does not settle whether the company’s platform will become broadly adopted. It gives Opal more capacity to demonstrate what happens when the underlying model gets closer to the biology.

What Comes Next

The immediate job is execution. Opal Therapeutics has $1.25M in NSF Phase II funding designated for scaling laboratory infrastructure, organoid manufacturing, imaging, and inflammation assay throughput. The company has already reported production at a scale of tens of thousands of organoids, a 1st paid customer in Papaya, and a Material Transfer Agreement with Baylor College of Medicine. Now those pieces have to compound.

For sophisticated operators watching women’s health, the interesting signal is not simply that another biotechnology company received federal funding. Opal is attempting to build foundational discovery infrastructure around biological systems that historically have been difficult to reproduce using conventional models. The name works almost suspiciously well. Opal is operating in a field where considerable biological value has remained beneath the surface, partly because the tools available to examine it have limitations. The NSF just financed a larger window into that biology. What researchers and drug developers can see through it will determine how much the $1.25M ultimately matters.